Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sapheon brings in $8.6mm so far through its planned $18.5mm Series B venture round; closes at $19.8mm

Executive Summary

Vascular disease device developer Sapheon Inc. has raised $8.6mm through the first closing of its Series B venture round. It issued 4.8mm shares to 33 investors and hopes to bring in $18.5mm when the financing is completed. Aaron Berez, MD, former CEO of Chestnut Medical Technologies, will take a seat on the company’s board. Sapheon is developing the VenaSeal system to close the saphenous vein in cases of venous reflux disease.

Deal Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Biomaterials
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies